429 related articles for article (PubMed ID: 33956937)
1. Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
Toy M; Hutton D; Harris AM; Nelson N; Salomon JA; So S
Clin Infect Dis; 2022 Jan; 74(2):210-217. PubMed ID: 33956937
[TBL] [Abstract][Full Text] [Related]
2. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
6. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections.
Hutton DW; Toy M; Salomon JA; Conners EE; Nelson NP; Harris AM; So S
Sex Transm Dis; 2022 Jul; 49(7):517-525. PubMed ID: 35312661
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
9. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Toy M; Hutton DW; So SK
PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
11. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Yuan Y; Iloeje U; Li H; Hay J; Yao GB
Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
[TBL] [Abstract][Full Text] [Related]
14. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
Chaillon A; Rand EB; Reau N; Martin NK
Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.
Toy M; Onder FO; Idilman R; Kabacam G; Richardus JH; Bozdayi M; Akdogan M; Kuloglu Z; Kansu A; Schalm S; Yurdaydin C
Eur J Health Econ; 2012 Oct; 13(5):663-76. PubMed ID: 22815098
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression.
Lee H; Kim BK; Jang S; Ahn SH
Clin Transl Gastroenterol; 2021 Feb; 12(2):e00299. PubMed ID: 33600103
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States.
Ogawa E; Yeo YH; Dang N; Le MH; Jeong D; Tran S; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2020 Apr; 3(4):e201844. PubMed ID: 32271388
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
